Interplay between histone acetylation/deacetylation and poly(ADP-ribosyl)ation in the development of ischemic tolerance in vitro

Neuropharmacology

Volumn 92, Issue , 2015, Pages 125-134

  Gerace, Elisabetta ^a   Landucci, Elisa ^a   Scartabelli, Tania ^a   Moroni, Flavio ^a   Chiarugi, Alberto ^a   Pellegrini Giampietro, Domenico E ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

HDAC inhibitors; Histone acetylation deacetylation; Ischemia tolerance; NMDA; Poly(ADPribosyl)ation; Preconditioning

Indexed keywords

4H THIENO[2,3 C]ISOQUINOLIN 5 ONE; BUTYRIC ACID; GLUCOSE; HISTONE DEACETYLASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N METHYL DEXTRO ASPARTIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXYGEN; UNCLASSIFIED DRUG; VORINOSTAT; ENZYME INHIBITOR; HISTONE; HYDROXAMIC ACID; N METHYLASPARTIC ACID;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN ISCHEMIA; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEACETYLATION; DRUG MECHANISM; ENZYME ACTIVITY; HIPPOCAMPAL CA1 REGION; HISTONE ACETYLATION; IN VITRO STUDY; ISCHEMIC PRECONDITIONING; ISCHEMIC TOLERANCE; NONHUMAN; PROTEIN PROTEIN INTERACTION; RAT; ACETYLATION; ANIMAL; ANOXIA; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; HIPPOCAMPUS; METABOLISM; NERVE CELL; NEWBORN; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; SIGNAL TRANSDUCTION; TIME; WISTAR RAT;

ACETYLATION; ANIMALS; ANIMALS, NEWBORN; ANOXIA; BUTYRIC ACID; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSE; HIPPOCAMPUS; HISTONES; HYDROXAMIC ACIDS; IN VITRO TECHNIQUES; N-METHYLASPARTATE; NEURONS; ORGAN CULTURE TECHNIQUES; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84922354071     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.01.008     Document Type: Article

References (57)

1. T. Abel, and R.S. Zukin Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders Curr. Opin. Pharmacol. 8 2008 57 64
2. S.L. Berger The complex language of chromatin regulation during transcription Nature 447 2007 407 412
3. V. Calvanese, E. Lara, A. Kahn, and M.F. Fraga The role of epigenetics in aging and age-related diseases Ageing Res. Rev. 8 2009 268 276
4. A. Chiarugi, E. Meli, M. Calvani, R. Picca, R. Baronti, E. Camaioni, G. Costantino, M. Marinozzi, D.E. Pellegrini-Giampietro, R. Pellicciari, and F. Moroni Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia J. Pharmacol. Exp. Ther. 305 2003 943 949
5. J.S. Choi, H.Y. Kim, J.H. Cha, and M.Y. Lee Ischemic preconditioning-induced activation of ERK1/2 in the rat hippocampus Neurosci. Lett. 409 2006 187 191
6. D.M. Chuang, Y. Leng, Z. Marinova, H.J. Kim, and C.T. Chiu Multiple roles of HDAC inhibition in neurodegenerative conditions Trends Neurosci. 32 2009 591 601
7. M. Cohen-Armon, L. Visochek, D. Rozensal, A. Kalal, I. Geistrikh, R. Klein, S. Bendetz-Nezer, Z. Yao, and R. Seger DNA-independent PARP-1 activation by phosphorylated ERK2 increases EIk1 activity: a link to histone acetylation Mol. Cell. 25 2007 297 308
8. S.R. D'Mello Histone deacetylases as targets for the treatment of human neurodegenerative diseases Drug News Perspect. 22 2009 513 524
9. D. Della-Morte, K.R. Dave, R.A. DeFazio, Y.C. Bao, A.P. Raval, and M.A. Perez-Pinzon Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway Neuroscience 159 2009 993 1002
10. S.I. Deutsch, R.B. Rosse, J. Mastropaolo, K.D. Long, and B.L. Gaskins Epigenetic therapeutic strategies for the treatment of neuropsychiatric disorders: ready for prime time? Clin. Neuropharmacol. 31 2008 104 119
11. U. Dirnagl, K. Becker, and A. Meisel Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use Lancet Neurol. 8 2009 398 412
12. S. Emanuele, M. Lauricella, and G. Tesoriere Histone deacetylase inhibitors: apoptotic effects and clinical implications Int. J. Oncol. 33 2008 637 646
13. M. Endres, A. Meisel, D. Biniszkiewicz, S. Namura, K. Prass, K. Ruscher, A. Lipski, R. Jaenisch, M.A. Moskowitz, and U. Dirnagl DNA methyltransferase contributes to delayed ischemic brain injury J. Neurosci. 20 2000 3175 3181
14. G. Faraco, T. Pancani, L. Formentini, P. Mascagni, S. Fossati, F. Leoni, F. Moroni, and A. Chiarugi Pharmacological inhibition of histone deacetylases (HDACs) by suberoylanilide hydroxamic acid (SAHA) specifically alters gene expression and reduces ischemic injury in the mouse brain Mol. Pharmacol. 70 2006 1876 1884
15. F. Gao, X.Y. Hu, X.J. Xie, Q.Y. Xu, Y.P. Wang, X.B. Liu, M.X. Xiang, Y. Sun, and J.A. Wang Heat shock protein 90 protects rat mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis via the PI3K/Akt and ERK1/2 pathways J. Zhejiang Univ. Sci. 11 2010 608 617
16. E. Gerace, T. Scartabelli, L. Formentini, E. Landucci, F. Moroni, A. Chiarugi, and D.E. Pellegrini-Giampietro Mild activation of poly(ADP-ribose) polymerase (PARP) is neuroprotective in rat hippocampal slice models of ischemic tolerance Eur. J. Neurosci. 36 2012 1993 2005
17. C.L. Gibson, and S.P. Murphy Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies J. Neurochem. 115 2010 806 813
18. J.M. Gidday Cerebral preconditioning and ischaemic tolerance Nat. Rev. Neurosci. 7 2006 437 448
19. S. Gravina, and J. Vijg Epigenetic factors in aging and longevity Pflügers Arch. 459 2010 247 258
20. S.S. Haenni, P.O. Hassa, M. Altmeyer, M. Fey, R. Imhof, and M.O. Hottiger Identification of lysines 36 and 37 of PARP-2 as targets for acetylation and auto-ADP-ribosylation Int. J. Biochem. Cell Biol. 40 2008 2274 2283
21. E. Hahnen, J. Hauke, C. Tränkle, I.Y. Eyüpoglu, B. Wirth, and I. Blümcke Histone deacetylase inhibitors: possible implications for neurodegenerative disorders Expert Opin. Investig. Drugs 17 2008 169 184
22. E. Jasek, M. Gajda, G.J. Lis, M. Jasinska, and J.A. Litwin Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines Anticancer Res. 34 2014 1849 1856
23. A.R. Jazirehi Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy Anticancer Drugs 21 2010 805 813
24. A.G. Kazantsev, and L.M. Thompson Therapeutic application of histone deacetylase inhibitors for central nervous system disorders Nat. Rev. Drug Discov. 7 2013 854 868
25. H.J. Kim, P. Leeds, and D.M. Chuang The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain J. Neurochem. 110 2009 1226 1240
26. H.J. Kim, M. Rowe, M. Ren, J.S. Hong, P.S. Chen, and D.M. Chuang Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action J. Pharmacol. Exp. Ther. 321 2007 892 901
27. T. Kouzarides Chromatin modifications and their function Cell 128 2007 693 705
28. R. Krishnakumar, M.J. Gamble, K.M. Frizzell, J.G. Berrocal, M. Kininis, and W.L. Kraus Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes Science 319 2008 819 821
29. A.A. Lane, and B.A. Chabner Histone deacetylase inhibitors in cancer therapy J. Clin. Oncol. 27 2009 5459 5468
30. B. Langley, C. Brochier, and M.A. Rivieccio Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke Stroke 40 2009 2899 2905
31. B. Langley, M.A. D'Annibale, K. Suh, I. Ayoub, A. Tolhurst, B. Bastan, L. Yang, M. Fisher, S. Cho, M.F. Beal, and R.R. Ratan Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection J. Neurosci. 28 2008 163 176
32. A. Lanzillotta, G. Pignataro, C. Branca, O. Cuomo, I. Sarnico, M. Benarese, L. Annunziato, P. Spano, and M. Pizzi Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window Neurobiol. Dis. 49 2013 177 189
33. J.M. Levenson, K.J. O'Riordan, K.D. Brown, M.A. Trinh, D.L. Molfese, and J.D. Sweatt Regulation of histone acetylation during memory formation in the hippocampus J. Biol. Chem. 279 2004 40545 40559
34. B. Miao, X.H. Yin, D.S. Pei, Q.G. Zhang, and G.Y. Zhang Neuroprotective effects of preconditioning ischemia on ischemic brain injury through down-regulating activation of JNK 1/2 via N-methyl-D-aspartate receptor mediated Akt1 activation J. Biol. Chem. 280 2005 21693 21699
35. T.P. Obrenovitch Molecular physiology of preconditioning-induced brain tolerance to ischemia Physiol. Rev. 88 2008 211 247
36. D.E. Pellegrini-Giampietro, A. Cozzi, F. Peruginelli, P. Leonardi, E. Meli, R. Pellicciari, and F. Moroni 1-Aminoindan-1,5-dicarboxylic acid and (S)-(+)-2-(3'-carboxybicyclo[1.1.1]pentyl)-glycine, two mGlu1 receptor-preferring antagonists, reduce neuronal death in in vitro and in vivo models of cerebral ischemia Eur. J. Neurosci. 11 1999 3637 3647
37. D.E. Pellegrini-Giampietro, F. Peruginelli, E. Meli, A. Cozzi, S. Albani Torregrossa, R. Pellicciari, and F. Moroni Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time-course and mechanisms Neuropharmacology 38 1999 1607 1619
38. R. Pellicciari, E. Camaioni, G. Costantino, M. Marinozzi, A. Macchiarulo, F. Moroni, and B. Natalini Towards new neuroprotective agents: design and synthesis of 4H-thieno[2,3-c] isoquinolin-5-one derivatives as potent PARP-1 inhibitors Farmaco 58 2003 851 858
39. X. Qi, T. Hosoi, Y. Okuma, M. Kaneco, and Y. Nomura Sodium 4-phenylbutyrate protects against cerebral ischemic injury Mol. Pharmacol. 66 2004 899 908
40. A.P. Raval, K.R. Dave, and M.A. Perez-Pinzon Resveratrol mimics ischemic preconditioning in the brain J. Cereb. Blood Flow Metab. 26 2006 1141 1147
41. M. Ren, Y. Leng, M. Jeong, P.R. Leeds, and D.M. Chuang Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction J. Neurochem. 89 2004 1358 1367
42. R.N. Saha, and K. Pahan HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis Cell Death Differ. 13 2006 539 550
43. F. Sananbenesi, and A. Fischer The epigenetic bottleneck of neurodegenerative and psychiatric diseases Biol. Chem. 390 2009 1145 1153
44. V. Schreiber, F. Dantzer, J.C. Ame, and G. de Murcia Poly(ADP-ribose): novel functions for an old molecule Nat. Rev. Mol. Cell Biol. 7 2006 517 528
45. S. Schweizer, A. Meisel, and S. Märschenz Epigenetic mechanisms in cerebral ischemia J. Cereb. Blood Flow Metab. 33 2013 1335 1346
46. M. Shamloo, A. Rytter, and T. Wieloch Activation of the extracellular signal-regulated protein kinase cascade in the hippocampal CA1 region in a rat model of global cerebral ischemic preconditioning Neuroscience 93 1999 81 88
47. D.I. Sinn, S.J. Kim, K. Chu, K.H. Jung, S.T. Lee, E.C. Song, J.M. Kim, D.K. Park, S.K. Lee, M. Kim, and J.K. Roh Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation Neurobiol. Dis. 26 2007 464 472
48. M.P. Stenzel-Poore, S.L. Stevens, J.S. King, and R.P. Simon Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes: a speculative synthesis Stroke 38 2007 680 685
49. J.W. Thompson, K.R. Dave, J.I. Young, and M.A. Perez-Pinzon Ischemic preconditioning alters the epigenetic profile of the brain from ischemic intolerance to ischemic tolerance Neurotherapeutics 10 2013 789 797
50. K.T. Thurn, S. Thomas, A. Moore, and P.N. Munster Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer Future Oncol. 7 2011 263 283
51. B. Wang, X.L. Zhu, Y. Kim, J. Li, S.Y. Huang, S. Saleem, R.C. Li, Y. Xu, S. Dore, and W.S. Cao Histone deacetylase inhibition activates transcription factor Nrf2 and protects against cerebral ischemic damage Free Radic. Biol. Med. 52 2012 928 936
52. A. Xuan, D. Long, J. Li, W. Ji, L. Hong, M. Zhang, and W. Zhang Neuroprotective effects of valproic acid following transient global ischemia in rats Life Sci. 90 2012 463 468
53. W. Yan, Z. Fang, Q. Yang, H. Dong, Y. Lu, C. Lei, and L. Xiong SirT1 mediates hyperbaric oxygen preconditioning-induced ischemia tolerance in rat brain J. Cereb. Blood Flow Metab. 33 2013 396 406
54. F. Yildrim, K. Gertz, G. Kronenberg, C. Harms, K.B. Fink, A. Meisel, and M. Endres Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury Exp. Neurol. 210 2008 531 542
55. L. Zhang, B. Chen, Y. Zhao, P.M. Dubielecka, L. Wei, G.J. Qin, Y.E. Chin, Y.G. Wang, and T.C. Zhao Inhibition of histone deacetylase-induced myocardial repair is mediated by c-kit in infarcted hearts J. Biol. Chem. 287 2012
56. Q.G. Zhang, R.M. Wang, D. Han, L.C. Yang, J. Li, and D.W. Bramm Preconditioning neuroprotection in global cerebral ischemia involves NMDA receptor-mediated ERK/JNK3 crosstalk Neurosci. Res. 63 2009 205 212
57. T.C. Zhao, G. Cheng, L.X. Zhang, Y.T. Tseng, and J.F. Padbury Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury Cardiovasc. Res. 76 2007 473 481